Shire PLC (LON:SHP)‘s stock had its “hold” rating restated by analysts at Liberum Capital in a report released on Monday. They presently have a GBX 4,900 ($63.47) target price on the biopharmaceutical company’s stock. Liberum Capital’s price target points to a potential upside of 13.31% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. Deutsche Bank AG reiterated a “buy” rating and set a GBX 6,300 ($81.61) target price on shares of Shire PLC in a research report on Friday, April 7th. Societe Generale reiterated a “buy” rating and set a GBX 6,200 ($80.31) target price on shares of Shire PLC in a research report on Thursday, March 23rd. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a report on Wednesday, April 12th. Berenberg Bank restated a “buy” rating on shares of Shire PLC in a report on Wednesday, April 12th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a GBX 6,800 ($88.08) price target on shares of Shire PLC in a report on Wednesday, April 12th. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Shire PLC presently has an average rating of “Buy” and an average target price of GBX 6,005.60 ($77.79).
Shares of Shire PLC (LON:SHP) opened at 4324.50 on Monday. The company’s 50 day moving average is GBX 4,526.50 and its 200-day moving average is GBX 4,615.89. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,377.00. The company’s market capitalization is GBX 39.10 billion.
COPYRIGHT VIOLATION NOTICE: This news story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/markets/2284079/shire-plcs-shp-hold-rating-reiterated-at-liberum-capital.html.
In other news, insider Dominic Blakemore acquired 152 shares of the business’s stock in a transaction on Friday, June 30th. The shares were purchased at an average cost of GBX 4,255 ($55.12) per share, with a total value of £6,467.60 ($8,377.72).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284079/shire-plcs-shp-hold-rating-reiterated-at-liberum-capital.html
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.